Iratumumab

DB05550InvestigationalProtein Based Therapies

Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for...

Mechanism: Pharmacologically active on Tumor necrosis factor receptor superfamily member 8
Curator reviewed
Primary indication: Investigated for use/treatment in lymphoma (unspecified).Curator reviewed
Also known as: 5F11 monoclonal antibody
Code names: MDX-060

Resolves to

Compound

UNIIAYH22O1B1UCAS640735-09-7

Targets

P28908TNFRSF8

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Iratumumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account